Abstract 246: Discovery and mechanistic characterisation of the first oral bioavailable FEN1 inhibitor for treatment of HRD and EWS cancers and combination with various DDR inhibitors.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Lars T. Burgdorf, Julien Lefranc, Lucy Armstrong, Roch Boivin, Joerg Bomke, Xiaoling Chen, Paula Costales, Owen A. Davis, Lizbeth DeSelm, Elias Elinati, Maria Filipa Pinto, Bruce Follows, Alessandro Galbiati, Catherine Jorand-Lebrun, Timothea Konstantinou, Julian Kreis, Claudio A. Lademann, Birgitta Leuthner, Jayesh B. Majithiya, Balca R. Mardin, Bethany Mason, Claire L. McWhirter, Djordje Musil, Ulrich Pehl, David Perera, Silvia Peripolli, Carl Petersson, Eeson Rajendra, Christin Rakers, Ada Sala-Hojman, Graeme C. Smith, Fiona Sorrell, Ana Toste Rêgo, Helen M. Robinson, Frank T. Zenke, Robert A. Heald, Sam E. Mann
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148632265
Cites:
Cited by:
Related to: